NewAmsterdam Pharma Company NV Ordinary Shares

Yahoo Finance • 2 months ago

NewAmsterdam Pharma reports Q2 results

* NewAmsterdam Pharma press release [https://seekingalpha.com/pr/20190665-newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financial-results] (NASDAQ:NAMS [https://seekingalpha.com/symbol/NAMS]): Q2 net loss of $1... Full story

Yahoo Finance • 2 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

–European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine... Full story

Yahoo Finance • 2 months ago

Obicetrapib shows promise in reducing Alzheimer's biomarkers

NAARDEN/MIAMI - NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its experimental drug obicetrapib significantly reduced plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, according to data from a prespecified ana... Full story

Yahoo Finance • 2 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting C... Full story

Yahoo Finance • 3 months ago

NewAmsterdam Pharma updates employment agreement with chief scientific officer

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced Friday that it has entered into an amended and restated employment agreement with Dr. John Kastelein, the company’s chief scientific officer and director. The agreement, effective as... Full story

Yahoo Finance • 3 months ago

NAMS Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of NewAmsterdam Pharma Company N V (Symbol: NAMS) crossed above their 200 day moving average of $20.32, changing hands as high as $21.26 per share. NewAmsterdam Pharma Company N V shares are currently tradi... Full story

Yahoo Finance • 3 months ago

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story

Yahoo Finance • 4 months ago

NewAmsterdam Pharma's SWOT analysis: stock poised for cardiovascular breakthrough

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is making waves in the cardiovascular drug market with its lead asset, obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor. As the company progresses through critical clinical t... Full story

Yahoo Finance • 4 months ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both the full ITT population (p<0.002) and... Full story

Yahoo Finance • 4 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicin... Full story

Yahoo Finance • 5 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 data showed that obicetrapib as an adjunct to statins, wheth... Full story

Yahoo Finance • 5 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicin... Full story

Yahoo Finance • 5 months ago

Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) stands against other Guru stocks to invest i... Full story

Yahoo Finance • 5 months ago

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medic... Full story

Yahoo Finance • 7 months ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- -- Phase 3 PREVAIL CVOT remains on track -- -- $834.2 million in cash, cash equivalents... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Second Quarter 2024 Earnings: Beats Expectations

NewAmsterdam Pharma (NASDAQ:NAMS) Second Quarter 2024 Results Key Financial Results Net loss: US$39.0m (loss widened by 1.9% from 2Q 2023). US$0.41 loss per share. earnings-and-revenue-growth All figures shown in the chart above are for... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma N.V. -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma N.V Enrollment to continue to the end of April to accommodate strong patient and site interest NAARDEN, the Netherlands and MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “... Full story

Yahoo Finance • 2 years ago

Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023

Round co-led by Forbion and EQT Life Sciences Financing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS) and additional pipeline programs Successful fundraising d... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 – -- Announced initial data from Phase 2a clinical trial evaluating obicetrapib in patients with early Alz... Full story